🇪🇺 Zenapax in European Union

EMA authorised Zenapax on 26 February 1999

Marketing authorisations

EMA — authorised 26 February 1999

  • Status: approved

EMA — authorised 1 July 2016

  • Application: EMEA/H/C/003862
  • Marketing authorisation holder: Biogen Idec Ltd
  • Local brand name: Zinbryta
  • Indication: Zinbryta is indicated in adult patients for the treatment of relapsing forms of multiple sclerosis (RMS).
  • Status: withdrawn

Read official source →

Zenapax in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Immunology approved in European Union

Frequently asked questions

Is Zenapax approved in European Union?

Yes. EMA authorised it on 26 February 1999; EMA authorised it on 1 July 2016.

Who is the marketing authorisation holder for Zenapax in European Union?

Hoffman-La Roche is the originator. The local marketing authorisation holder may differ — check the official source linked above.